Cargando…

Lithium chloride increases sensitivity to photon irradiation treatment in primary mesenchymal colon cancer cells

Colorectal cancer (CRC) is the third most prevalent type of cancer worldwide. It is also the second most common cause of cancer-associated mortality; it accounted for about 9.2% of all cancer deaths in 2018, most of which were due to resistance to therapy. The main treatment for CRC is surgery, gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Cammarota, Francesca, Conte, Andrea, Aversano, Antonietta, Muto, Paolo, Ametrano, Gianluca, Riccio, Patrizia, Turano, Mimmo, Valente, Valeria, Delrio, Paolo, Izzo, Paola, Pierantoni, Giovanna Maria, De Rosa, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002976/
https://www.ncbi.nlm.nih.gov/pubmed/32016459
http://dx.doi.org/10.3892/mmr.2020.10956
_version_ 1783494448652484608
author Cammarota, Francesca
Conte, Andrea
Aversano, Antonietta
Muto, Paolo
Ametrano, Gianluca
Riccio, Patrizia
Turano, Mimmo
Valente, Valeria
Delrio, Paolo
Izzo, Paola
Pierantoni, Giovanna Maria
De Rosa, Marina
author_facet Cammarota, Francesca
Conte, Andrea
Aversano, Antonietta
Muto, Paolo
Ametrano, Gianluca
Riccio, Patrizia
Turano, Mimmo
Valente, Valeria
Delrio, Paolo
Izzo, Paola
Pierantoni, Giovanna Maria
De Rosa, Marina
author_sort Cammarota, Francesca
collection PubMed
description Colorectal cancer (CRC) is the third most prevalent type of cancer worldwide. It is also the second most common cause of cancer-associated mortality; it accounted for about 9.2% of all cancer deaths in 2018, most of which were due to resistance to therapy. The main treatment for CRC is surgery, generally associated with chemotherapy, radiation therapy and combination therapy. However, while chemo-radiotherapy kills differentiated cancer cells, mesenchymal stem-like cells are resistant to this treatment, and this can give rise to therapy-resistant tumors. Our previous study isolated T88 primary colon cancer cells from a patient with sporadic colon cancer. These cells exhibited mesenchymal and epithelial features, high levels of epithelial-to-mesenchymal transition transcription factors, and stemness markers. In addition, it was revealed that lithium chloride (LiCl), a specific glycogen synthase kinase (GSK)-3β inhibitor, induced both the mesenchymal-to-epithelial transition and differentiation, and also reduced cell migration, stemness features and cell plasticity in these primary colon cancer cells. The aim of the present study was to investigate the effect of LiCl treatment on the viability of primary colon cancer cells exposed to 7 Gy delivered by high-energy photon beams, which corresponds to 6 megavolts of energy. To achieve this aim, the viability of irradiated T88 cells was compared with that of irradiated T88 cells pre-treated with LiCl. As expected, it was observed that LiCl sensitized primary colon cancer cells to high-energy photon irradiation treatment. Notably, the decrease in cell viability was greater with combined therapy than with irradiation alone. To explore the molecular basis of this response, the effect of LiCl on the expression of Bax, p53 and Survivin, which are proteins involved in the apoptotic mechanism and in death escape, was analyzed. The present study revealed that LiCl upregulated the expression of pro-apoptotic proteins and downregulated the expression of proteins involved in survival. These effects were enhanced by high-energy photon irradiation, suggesting that LiCl could be used to sensitize colon cancer cells to radiation therapy.
format Online
Article
Text
id pubmed-7002976
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-70029762020-02-12 Lithium chloride increases sensitivity to photon irradiation treatment in primary mesenchymal colon cancer cells Cammarota, Francesca Conte, Andrea Aversano, Antonietta Muto, Paolo Ametrano, Gianluca Riccio, Patrizia Turano, Mimmo Valente, Valeria Delrio, Paolo Izzo, Paola Pierantoni, Giovanna Maria De Rosa, Marina Mol Med Rep Articles Colorectal cancer (CRC) is the third most prevalent type of cancer worldwide. It is also the second most common cause of cancer-associated mortality; it accounted for about 9.2% of all cancer deaths in 2018, most of which were due to resistance to therapy. The main treatment for CRC is surgery, generally associated with chemotherapy, radiation therapy and combination therapy. However, while chemo-radiotherapy kills differentiated cancer cells, mesenchymal stem-like cells are resistant to this treatment, and this can give rise to therapy-resistant tumors. Our previous study isolated T88 primary colon cancer cells from a patient with sporadic colon cancer. These cells exhibited mesenchymal and epithelial features, high levels of epithelial-to-mesenchymal transition transcription factors, and stemness markers. In addition, it was revealed that lithium chloride (LiCl), a specific glycogen synthase kinase (GSK)-3β inhibitor, induced both the mesenchymal-to-epithelial transition and differentiation, and also reduced cell migration, stemness features and cell plasticity in these primary colon cancer cells. The aim of the present study was to investigate the effect of LiCl treatment on the viability of primary colon cancer cells exposed to 7 Gy delivered by high-energy photon beams, which corresponds to 6 megavolts of energy. To achieve this aim, the viability of irradiated T88 cells was compared with that of irradiated T88 cells pre-treated with LiCl. As expected, it was observed that LiCl sensitized primary colon cancer cells to high-energy photon irradiation treatment. Notably, the decrease in cell viability was greater with combined therapy than with irradiation alone. To explore the molecular basis of this response, the effect of LiCl on the expression of Bax, p53 and Survivin, which are proteins involved in the apoptotic mechanism and in death escape, was analyzed. The present study revealed that LiCl upregulated the expression of pro-apoptotic proteins and downregulated the expression of proteins involved in survival. These effects were enhanced by high-energy photon irradiation, suggesting that LiCl could be used to sensitize colon cancer cells to radiation therapy. D.A. Spandidos 2020-03 2020-01-21 /pmc/articles/PMC7002976/ /pubmed/32016459 http://dx.doi.org/10.3892/mmr.2020.10956 Text en Copyright: © Cammarota et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Cammarota, Francesca
Conte, Andrea
Aversano, Antonietta
Muto, Paolo
Ametrano, Gianluca
Riccio, Patrizia
Turano, Mimmo
Valente, Valeria
Delrio, Paolo
Izzo, Paola
Pierantoni, Giovanna Maria
De Rosa, Marina
Lithium chloride increases sensitivity to photon irradiation treatment in primary mesenchymal colon cancer cells
title Lithium chloride increases sensitivity to photon irradiation treatment in primary mesenchymal colon cancer cells
title_full Lithium chloride increases sensitivity to photon irradiation treatment in primary mesenchymal colon cancer cells
title_fullStr Lithium chloride increases sensitivity to photon irradiation treatment in primary mesenchymal colon cancer cells
title_full_unstemmed Lithium chloride increases sensitivity to photon irradiation treatment in primary mesenchymal colon cancer cells
title_short Lithium chloride increases sensitivity to photon irradiation treatment in primary mesenchymal colon cancer cells
title_sort lithium chloride increases sensitivity to photon irradiation treatment in primary mesenchymal colon cancer cells
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002976/
https://www.ncbi.nlm.nih.gov/pubmed/32016459
http://dx.doi.org/10.3892/mmr.2020.10956
work_keys_str_mv AT cammarotafrancesca lithiumchlorideincreasessensitivitytophotonirradiationtreatmentinprimarymesenchymalcoloncancercells
AT conteandrea lithiumchlorideincreasessensitivitytophotonirradiationtreatmentinprimarymesenchymalcoloncancercells
AT aversanoantonietta lithiumchlorideincreasessensitivitytophotonirradiationtreatmentinprimarymesenchymalcoloncancercells
AT mutopaolo lithiumchlorideincreasessensitivitytophotonirradiationtreatmentinprimarymesenchymalcoloncancercells
AT ametranogianluca lithiumchlorideincreasessensitivitytophotonirradiationtreatmentinprimarymesenchymalcoloncancercells
AT ricciopatrizia lithiumchlorideincreasessensitivitytophotonirradiationtreatmentinprimarymesenchymalcoloncancercells
AT turanomimmo lithiumchlorideincreasessensitivitytophotonirradiationtreatmentinprimarymesenchymalcoloncancercells
AT valentevaleria lithiumchlorideincreasessensitivitytophotonirradiationtreatmentinprimarymesenchymalcoloncancercells
AT delriopaolo lithiumchlorideincreasessensitivitytophotonirradiationtreatmentinprimarymesenchymalcoloncancercells
AT izzopaola lithiumchlorideincreasessensitivitytophotonirradiationtreatmentinprimarymesenchymalcoloncancercells
AT pierantonigiovannamaria lithiumchlorideincreasessensitivitytophotonirradiationtreatmentinprimarymesenchymalcoloncancercells
AT derosamarina lithiumchlorideincreasessensitivitytophotonirradiationtreatmentinprimarymesenchymalcoloncancercells